Multiple sclerosis: Therapeutic update

Archives of Neurology

Volumn 56, Issue 3, 1999, Pages 277-280

  Tselis, Alexandros C ^a,b   Lisak, Robert P ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DETROIT RECEIVING HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; CORTICOSTEROID; GLATIRAMER; IMMUNOGLOBULIN; INTERFERON BETA SERINE; METHYLPREDNISOLONE; PLACEBO; PREDNISONE;

CLINICAL TRIAL; DEMYELINATING DISEASE; DEPRESSION; FLU LIKE SYNDROME; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MULTIPLE SCLEROSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RELAPSE; REMISSION; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032988782     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.56.3.277     Document Type: Review

References (17)

1. IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Neurology. 1993;43:655-661.
2. Paty DW. Li DKB, and the UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis, II. Neurology. 1993;43:662-667.
3. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: the Extended Disability Status Scale Neurology. 1983;33:1444-1452.
4. IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/ MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology. 1995;45:1277-1285.
5. European Study Group in Interferon beta-1b in Secondary Progressive MS. Placebo-controlled multicentre randomized trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet. 1998;352:1491-1497.
6. Lublin FD, Whitaker JN, Eidelman BH, et al. Management of patients receiving interferon beta-1b for multiple sclerosis. Neurology. 1996;46:12-18.
7. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol. 1996;39:285-294.
8. Pozzilli C, Bastianello S, Koudriavtseva T, et al. Magnetic resonance imaging changes with recombinant human interferon-b-1a: a short term study in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry. 1996;61:251-258.
9. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomized double-blind placebo controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet. 1998;352:1498-1504.
10. R) in the treatment of relapsing-remitting multiple sclerosis: the clinical results of a large multicenter study. Multiple Sclerosis. 1997;3:269.
11. Teitelbaum D. Meshorer A. Hirshfeld T. et al. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol. 1971;1:242-248.
12. Johnson KM, Brooks BR, Cohen JA, et al. Copolymer-1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology. 1995;45:1268-1276.
13. Johnson KM, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology. 1998;50:701-708.
14. Jeffrey D. Alshami E. Allogeneic bone marrow transplantation in multiple sclerosis [abstract]. Neurology. 1998;50:A147.
15. Beck RW, Cleary PA, Anderson MM, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med. 1992;326:581-588.
16. Barnes D, Hughes RAC, Morris RW, et al. Randomized trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis Lancet. 1997; 349:902-906.
17. Alam SM, Kyriakides T, Lawden M, Newman PK. Methylprednisolone in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1993;56:1219-1220.